Low-Dose Oral Minoxidil And Topical Minoxidil: Consensus Recommendations For Managing Male And Female Pattern Hair Loss In Hair Transplant Patients Using A Modified Delphi Process

    March 2026 in “ Figshare ”
    Aditya K. Gupta, Mesbah Talukder, Greg Williams, Haitham Abdelhamid, Yagiz Matthew Akiska, David M. Alpeter, Scott A. Boden, Randa Erfan, Bessam Farjo, Nilofer Farjo, Steven Gabel, James A. Harris, Karl Hekimian, Sharon A. Keene, Jennifer Krejci-Manwaring, Robert T. Leonard, Luis A. Nader, Damkerng Pathomvanich, David Perez-Meza, Nicole E. Rogers, Paul T. Rose, Marie A. Schambach, Ronald L. Shapiro, Mayank Singh, Dow B. Stough, Robert H. True, Sara M. Wasserbauer, Ryan J. Welter
    From the encyclopedia
    Hair Transplant →

    Hair transplantation moves DHT-resistant follicles from a donor area (back and sides of the scalp) into thinning or bald areas. The transplanted hair is generally permanent, though surrounding native hair can keep thinning.

    Minoxidil →

    An essential vasodilator with some anti-androgenic effects

    Image
    Studysummary This study developed expert consensus guidelines on using low-dose oral and topical minoxidil for pattern hair loss around hair transplant surgery, recommending specific doses, monitoring practices, and timing of use for both male and female patients.
    Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
    This study provides consensus-based recommendations for the use of low-dose oral minoxidil (LDOM) and topical minoxidil in managing male and female pattern hair loss (MPHL and FPHL) in hair transplant patients. An international panel of hair transplant surgeons used a modified Delphi process to agree on guidelines, including checking body weight and blood pressure before starting LDOM. Recommended starting doses are 1.25–2.5 mg/day for MPHL and 0.625–1.25 mg/day for FPHL, with maximum doses of 5 mg and 2.5 mg, respectively. Clinical response is expected within 4–6 months, and treatment can continue long-term if effective. LDOM can be taken 1–3 days post-surgery, while topical minoxidil can be applied 7–14 days after transplant. Minoxidil is effective on the frontal scalp and vertex but should be avoided during pregnancy and breastfeeding. These guidelines aim to standardize the integration of LDOM and topical minoxidil in hair transplant care.
    Discuss this study in the Community →